AlphaQuest LLC Trims Stake in Humana Inc. (NYSE:HUM)

AlphaQuest LLC lowered its position in Humana Inc. (NYSE:HUM) by 71.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 629 shares of the insurance provider’s stock after selling 1,583 shares during the period. AlphaQuest LLC’s holdings in Humana were worth $160,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Transcend Capital Advisors LLC boosted its holdings in Humana by 399.7% in the 4th quarter. Transcend Capital Advisors LLC now owns 3,643 shares of the insurance provider’s stock worth $924,000 after buying an additional 2,914 shares during the period. FNY Investment Advisers LLC boosted its holdings in shares of Humana by 6,647.5% during the 4th quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider’s stock valued at $6,916,000 after purchasing an additional 26,856 shares during the last quarter. Retirement Systems of Alabama boosted its holdings in shares of Humana by 735.9% during the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock valued at $55,563,000 after purchasing an additional 192,801 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Humana by 7.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 964,926 shares of the insurance provider’s stock valued at $244,811,000 after purchasing an additional 65,735 shares during the last quarter. Finally, PDT Partners LLC boosted its holdings in shares of Humana by 190.0% during the 3rd quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider’s stock valued at $1,286,000 after purchasing an additional 2,660 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

Humana stock opened at $264.39 on Tuesday. The firm has a market capitalization of $31.91 billion, a P/E ratio of 26.57, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The company’s 50-day moving average is $271.39 and its 200 day moving average is $278.89. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76.

Humana (NYSE:HUM) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Research analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.34%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on HUM. Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 price objective on shares of Humana in a report on Wednesday, February 12th. StockNews.com downgraded shares of Humana from a “buy” rating to a “hold” rating in a report on Tuesday. Piper Sandler increased their price objective on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. Truist Financial increased their price objective on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $283.00 target price on shares of Humana in a research report on Wednesday, February 12th. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.